Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
856 questions in 87 reviews · Cystic Fibrosis and Genetic Disorders
current versionsNo studies 856 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs AAD Time to next exacerbation · adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs AAD Participant satisfaction or preference · adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering other aerosolised medications: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Quality of life · adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering other aerosolised medications: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Serum deposition Cmax · adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT Quality of life · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering other aerosolised medications: VMT and AAD tidal breathing mode (TBM) vs VMT and AAD target inhalation mode (TIM) Time to next exacerbation · adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs ultrasonic nebulisers Quality of life · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs ultrasonic nebulisers Serum deposition Cmax · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ nebulisers for delivering other aerosolised medications: conventional systems vs ultrasonic nebulisers Time to next exacerbation · children and adults with cystic fibrosis Nebuliser systems for drug delivery in cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs CCPT Quality of life · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs PEP mask therapy Adverse events · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs PEP mask therapy FEV1: % predicted (change from baseline) · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs PEP mask therapy FVC: % predicted (change from baseline) · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs PEP mask therapy Sputum weight (change from baseline) · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs PEP mask therapy Number of pulmonary exacerbations · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs OD Adverse events · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs CCPT Personal preference · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs OD Number of pulmonary exacerbations · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs other breathing techniques Adverse events · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs other breathing techniques Number of pulmonary exacerbations · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs CCPT Adverse events · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs exercise Personal preference · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs exercise Sputum weight (change from baseline) · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs CCPT Sputum weight (change from baseline) · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ACBT vs PEP mask therapy Personal preference · people with cystic fibrosis Active cycle of breathing technique for cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – bisphosphonates vs placebo or no treatment BMD Z score (total hip/femoral neck) · adults with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR BMD Z score (wrist) Â · people with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Incidence of fractures · people with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Mobility · people with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life · people with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse effects of treatment · people with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – zinc vs placebo BMD Z score (wrist) · children and adults with β‐thalassaemia major and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – zinc vs placebo Incidence of fractures · children and adults with β‐thalassaemia major and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – zinc vs placebo Mobility · children and adults with β‐thalassaemia major and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – bisphosphonates vs placebo or no treatment BMD Z score (lumbar spine) · adults with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – zinc vs placebo Quality of life · children and adults with β‐thalassaemia major and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – zinc vs placebo Adverse effects of treatment · children and adults with β‐thalassaemia major and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – denosumab vs placebo Incidence of fractures · adults with β‐thalassaemia and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – denosumab vs placebo Mobility · adults with β‐thalassaemia and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – denosumab vs placebo Quality of life · adults with β‐thalassaemia and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – denosumab vs placebo Adverse effects of treatment · adults with β‐thalassaemia and low bone mass Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – strontium ranelate vs placebo BMD Z score (total hip/femoral neck) · women with low bone mass and β‐thalassaemia Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – bisphosphonates vs placebo or no treatment BMD Z score (wrist) · adults with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – strontium ranelate vs placebo BMD Z score (wrist) · women with low bone mass and β‐thalassaemia Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – strontium ranelate vs placebo Incidence of fractures · women with low bone mass and β‐thalassaemia Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – strontium ranelate vs placebo Mobility · women with low bone mass and β‐thalassaemia Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – strontium ranelate vs placebo Adverse effects of treatment · women with low bone mass and β‐thalassaemia Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings – bisphosphonates vs placebo or no treatment Mobility · adults with β‐thalassaemia and osteoporosis Treatment for osteoporosis in people with beta‐thalassaemia (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ monotherapy: cavosonstat vs placebo FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ monotherapy: cavosonstat vs placebo Time to first pulmonary exacerbation · adults and children with cystic fibrosis Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene… (2023) · Cochrane | no estimate extracted | NR | No studies |